Qianjiang Yongan Pharmaceutical Co., Ltd.

XSEC:002365 Stock Report

Market Cap: CN¥2.4b

Qianjiang Yongan Pharmaceutical Management

Management criteria checks 2/4

Qianjiang Yongan Pharmaceutical's CEO is Rengui Hong, appointed in Jun 2021, has a tenure of 3.5 years. directly owns 0.062% of the company’s shares, worth CN¥1.47M. The average tenure of the management team and the board of directors is 8.9 years and 3.5 years respectively.

Key information

Rengui Hong

Chief executive officer

CN¥1.9m

Total compensation

CEO salary percentagen/a
CEO tenure3.5yrs
CEO ownership0.06%
Management average tenure8.9yrs
Board average tenure3.5yrs

Recent management updates

Recent updates


CEO

Rengui Hong (41 yo)

3.5yrs

Tenure

CN¥1,909,100

Compensation

Mr. Rengui Hong is Managing Director and Director of Qianjiang Yongan Pharmaceutical Co. Ltd. from June 28, 2021.


Leadership Team

NamePositionTenureCompensationOwnership
Rengui Hong
MD & Director3.5yrsCN¥1.91m0.062%
CN¥ 1.5m
Baineng Luo
Head of the Audit Department8.3yrsCN¥522.50k0.062%
CN¥ 1.5m
Shi Hao Dong
Deputy General Manager18.8yrsCN¥1.09m0.37%
CN¥ 8.9m
Xiquan Fang
Deputy General Manager11.4yrsCN¥1.74m0.097%
CN¥ 2.3m
Zhihua Wang
Deputy General Manager9.5yrsCN¥918.30k0.097%
CN¥ 2.3m
Shaobo Li
Senior Management5.8yrsCN¥627.70k0.017%
CN¥ 403.5k

8.9yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 002365's management team is seasoned and experienced (8.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Rengui Hong
MD & Director3.5yrsCN¥1.91m0.062%
CN¥ 1.5m
Yong Chen
Chairman18.8yrsCN¥2.95m21.79%
CN¥ 517.3m
Yuxi Wu
Chairman of the Supervisory Board3.5yrsCN¥166.70k0.19%
CN¥ 4.5m
Chunxiang Zhao
Independent Director3.5yrsCN¥80.00kno data
Bing Zhang
Independent Director3.5yrsCN¥80.00kno data
Xu Wu
Supervisor9.5yrsno datano data
Zidi Chen
Non-Independent Directorless than a yearCN¥367.60kno data
Wen Chen
Independent Directorless than a yearno datano data

3.5yrs

Average Tenure

46yo

Average Age

Experienced Board: 002365's board of directors are considered experienced (3.5 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 06:17
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Qianjiang Yongan Pharmaceutical Co., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Bin WuChina Merchants Securities Co. Ltd.
Peng LiuGuosen Securities Co., Ltd.